The evolution of endometrial carcinoma classification through application of immunohistochemistry and molecular diagnostics: past, present and future

No abstract is available for this paper.

• Publication year

  2018

• Venue

  Virchows Archiv

• Publication date

  2018-06-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1007/s00428-017-2279-8PMID 29234950
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A Selective Biomarker Panel Increases the Reproducibility and the Accuracy in Endometrial Biopsy Diagnosis

  2017cited by this paper
• The changing landscape of gynaecological cancer diagnosis: implications for histopathological practice in the 21st century

  2017cited by this paper
• Prognostic and predictive biomarkers in breast cancer: Past, present and future.

  2017cited by this paper
• Molecular approaches for classifying endometrial carcinoma.

  2017cited by this paper
• Infrequent Immunohistochemical Expression of Napsin A in Endometrial Carcinomas

  2017cited by this paper
• Interobserver Agreement in Endometrial Carcinoma Histotype Diagnosis Varies Depending on The Cancer Genome Atlas (TCGA)-based Molecular Subgroup

  2017cited by this paper
• Loss of expression of SMARCA4 (BRG1), SMARCA2 (BRM) and SMARCB1 (INI1) in undifferentiated carcinoma of the endometrium is not uncommon and is not always associated with rhabdoid morphology

  2017cited by this paper
• Genetic analysis of uterine aspirates improves the diagnostic value and captures the intra-tumor heterogeneity of endometrial cancers

  2017cited by this paper
• Confirmation of ProMisE: A simple, genomics‐based clinical classifier for endometrial cancer

  2017cited by this paper
• Interobserver Variability in the Diagnosis of Uterine High-Grade Endometrioid Carcinoma.

  2016cited by this paper
• Survival Differences Among Uterine Papillary Serous, Clear Cell and Grade 3 Endometrioid Adenocarcinoma Endometrial Cancers: A National Cancer Database Analysis

  2016cited by this paper
• TP53 Mutational Spectrum in Endometrioid and Serous Endometrial Cancers

  2016cited by this paper
• Practical issues in the diagnosis of serous carcinoma of the endometrium

  2016cited by this paper
• Immunotherapy in Endometrial Cancer: In the Nick of Time

  2016cited by this paper
• Endometrial Carcinomas with POLE Exonuclease Domain Mutations Have a Favorable Prognosis

  2016cited by this paper
• Clinicopathologic implications of DNA mismatch repair status in endometrial carcinomas.

  2016cited by this paper
• Histopathological features of endometrial carcinomas associated with POLE mutations: implications for decisions about adjuvant therapy

  2016cited by this paper
• Improved Risk Assessment by Integrating Molecular and Clinicopathological Factors in Early-stage Endometrial Cancer—Combined Analysis of the PORTEC Cohorts

  2016cited by this paper
• Loss of switch/sucrose non-fermenting complex protein expression is associated with dedifferentiation in endometrial carcinomas

  2016cited by this paper
• Optimized p53 immunohistochemistry is an accurate predictor of TP53 mutation in ovarian carcinoma

  2016cited by this paper
• Immunophenotypic features of dedifferentiated endometrial carcinoma – insights from BRG1/INI1‐deficient tumours

  2016cited by this paper
• Stromal p16 expression is significantly increased in endometrial carcinoma

  2016cited by this paper
• Clinicopathologic and Immunohistochemical Characterization of Dedifferentiated Endometrioid Adenocarcinoma

  2016cited by this paper
• Molecular classification of endometrial carcinoma on diagnostic specimens is highly concordant with final hysterectomy: Earlier prognostic information to guide treatment.

  2016cited by this paper
• Calibration and Optimization of p53, WT1, and Napsin A Immunohistochemistry Ancillary Tests for Histotyping of Ovarian Carcinoma: Canadian Immunohistochemistry Quality Control (CIQC) Experience

  2016cited by this paper
• Undifferentiated Carcinoma of the Endometrium: An Expanded Immunohistochemical Analysis Including PAX-8 and Basal-Like Carcinoma Surrogate Markers

  2016cited by this paper
• Mutation profile and clinical outcome of mixed endometrioid-serous endometrial carcinomas are different from that of pure endometrioid or serous carcinomas

  2015cited by this paper
• Morphologic and Molecular Characteristics of Mixed Epithelial Ovarian Cancers

  2015cited by this paper
• Uterine cancer in the writings of Byzantine physicians.

  2015cited by this paper
• A clinically applicable molecular-based classification for endometrial cancers

  2015cited by this paper
• SWI/SNF complex deficiency and mismatch repair protein expression in undifferentiated and dedifferentiated endometrial carcinoma

  2015cited by this paper
• Biomarkers and targeted systemic therapies in advanced non-small cell lung cancer.

  2015cited by this paper
• Targeted mutation analysis of endometrial clear cell carcinoma

  2015cited by this paper
• Molecular Analysis of Mixed Endometrial Carcinomas Shows Clonality in Most Cases

  2015cited by this paper
• Detection of DNA mismatch repair (MMR) deficiencies by immunohistochemistry can effectively diagnose the microsatellite instability (MSI) phenotype in endometrial carcinomas.

  2015cited by this paper
• Frequent Expression of Napsin A in Clear Cell Carcinoma of the Endometrium: Potential Diagnostic Utility

  2014cited by this paper
• Prognostic Significance of POLE Proofreading Mutations in Endometrial Cancer

  2014cited by this paper
• Immunohistochemical characterization of prototypical endometrial clear cell carcinoma—diagnostic utility of HNF‐1β and oestrogen receptor

  2014cited by this paper
• A 9-protein biomarker molecular signature for predicting histologic type in endometrial carcinoma by immunohistochemistry.

  2014cited by this paper
• Optimal protocol for PTEN immunostaining; role of analytical and preanalytical variables in PTEN staining in normal and neoplastic endometrial, breast, and prostatic tissues.

  2014cited by this paper
• Histologic and immunohistochemical analyses of endometrial carcinomas: experiences from endometrial biopsies in 358 consultation cases.

  2013cited by this paper
• Endometrial carcinoma: molecular alterations involved in tumor development and progression

  2013cited by this paper
• Reproducibility of histological cell type in high-grade endometrial carcinoma

  2013cited by this paper
• Histotype-Genotype Correlation in 36 High-grade Endometrial Carcinomas

  2013cited by this paper
• Poor Interobserver Reproducibility in the Diagnosis of High-grade Endometrial Carcinoma

  2013cited by this paper
• Integrated genomic characterization of endometrial carcinoma

  2013cited by this paper
• Should grade 3 endometrioid endometrial carcinoma be considered a type 2 cancer-a clinical and pathological evaluation.

  2012cited by this paper
• Prognosis of high-grade endometrial cancer: a comparison of serous-type and clear cell type to grade 3 endometrioid-type.

  2012cited by this paper
• Use of mutation profiles to refine the classification of endometrial carcinomas

  2012cited by this paper
• Mutation and Loss of Expression of ARID1A in Uterine Low-grade Endometrioid Carcinoma

  2011cited by this paper
• Clinical Assessment of PTEN Loss in Endometrial Carcinoma: Immunohistochemistry Out-Performs Gene Sequencing

  2011cited by this paper
• Subtype‐specific mutation of PPP2R1A in endometrial and ovarian carcinomas

  2011cited by this paper
• A Unique Spectrum of Somatic PIK3CA (p110α) Mutations Within Primary Endometrial Carcinomas

  2011cited by this paper
• High-Grade Endometrial Carcinoma: Serous and Grade 3 Endometrioid Carcinomas Have Different Immunophenotypes and Outcomes

  2010cited by this paper
• p53 overexpression in morphologically ambiguous endometrial carcinomas correlates with adverse clinical outcomes

  2010cited by this paper
• Endometrial carcinomas with ambiguous features.

  2010cited by this paper
• Lynch syndrome (hereditary non-polyposis colorectal cancer) and endometrial carcinoma

  2009cited by this paper
• Application of immunohistochemistry to gynecologic pathology.

  2009cited by this paper
• Histologic and immunohistochemical decision-making in endometrial adenocarcinoma

  2008cited by this paper
• Immunohistochemical Differences Between Mucinous and Microglandular Adenocarcinomas of the Endometrium and Benign Endocervical Epithelium

  2008cited by this paper
• Clinicopathologic Analysis of 187 High-grade Endometrial Carcinomas of Different Histologic Subtypes: Similar Outcomes Belie Distinctive Biologic Differences

  2007cited by this paper
• Reproducibility of grading systems for endometrial endometrioid carcinoma and their relation with pathologic prognostic parameters

  2007cited by this paper
• Identification of prognostically relevant and reproducible subsets of endometrial adenocarcinoma based on clustering analysis of immunostaining data

  2007cited by this paper
• High frequency of coexistent mutations of PIK3CA and PTEN genes in endometrial carcinoma.

  2005cited by this paper
• Uterine serous and grade 3 endometrioid carcinomas

  2004cited by this paper
• p16 Immunoreactivity May Assist in the Distinction Between Endometrial and Endocervical Adenocarcinoma

  2003cited by this paper
• Differential gene expression profile in endometrioid and nonendometrioid endometrial carcinoma: STK15 is frequently overexpressed and amplified in nonendometrioid carcinomas.

  2003cited by this paper
• The frequency of p53, k‐ras mutations, and microsatellite instability differs in uterine endometrioid and serous carcinoma

  2000cited by this paper
• Comparison of estrogen and progesterone receptor, Ki-67, and p53 immunoreactivity in uterine endometrioid carcinoma and endometrioid carcinoma with squamous, mucinous, secretory, and ciliated cell differentiation.

  1998cited by this paper
• A clinicopathologic study of endometrial carcinoma with special reference to new histological variants.

  1985cited by this paper
• Two pathogenetic types of endometrial carcinoma.

  1983cited by this paper
• Carcinoma of the endometrium: I. A clinicopathologic study of clear‐cell carcinoma and secretory carcinoma

  1982cited by this paper
• Uterine papillary serous carcinoma: A highly malignant form of endometrial adenocarcinoma

  1982cited by this paper
• Clear cell carcinoma of the endometrium: an analysis of 21 cases.

  1976cited by this paper
• Clear cell carcinoma of the endometrium. An analysis of 21 cases

  1976cited by this paper

• ET‐WOFS Metaheuristic Feature Selection Based Approach for Endometrial Cancer Classification and Detection

  2025cites this paper
• Amalgamated feature-based endometrial cancer prognosis using unsupervised segmented histopathological images

  2025cites this paper
• Tight junction disruption via claudin-6 overexpression promotes invasion and recurrence in high-grade endometrial tumors

  2025cites this paper
• Histotype and Grade Are of Prognostic Significance in the No Specific Molecular Prolife Molecular Subtype of Endometrial Carcinoma But Not in POLEmut, MMRd, or p53abn Endometrial Carcinomas: Results From a 2478 Case Series and a Systematic Review of the Literature.

  2025cites this paper
• Molecular pathology of endometrial cancer: recent advances in classification, prognostication, and management

  2024cites this paper
• Exploring The Efficacy of Multi-modal LLM In Endometrial Cancer Diagnosis

  2024cites this paper
• Utilization of immunohistochemistry in gynecologic tumors: An expert review

  2024cites this paper
• Estrogen Receptor (ER) and Progesterone Receptor (PgR) Expression in Endometrial Cancer—An Immunohistochemical Assessment

  2024cites this paper
• A Decade of Therapeutic Challenges in Synchronous Gynecological Cancers from the Bucharest Oncological Institute

  2023cites this paper
• Deep Learning for Diagnosis of Endometrial Cancer and Atypical Endometrial Hyperplasia

  2023cites this paper
• Mitochondrial Dynamics of Bcl-2 Family Proteins during 17-β-Estradiol-Induced Apoptosis Correlate with the Malignancy of Endometrial Cancer Cells.

  2023cites this paper
• Type II endometrial cancer: Incidence, overall and disease-free survival in Martinique

  2023cites this paper
• Comprehensive Approach to Genomic and Immune Profiling: Insights of a Real-World Experience in Gynecological Tumors

  2022cites this paper
• Biomarkers in Gynecologic Carcinomas

  2022cites this paper
• Low grade endometrial endometrioid adenocarcinoma: A review and update with emphasis on morphologic variants, mimics, immunohistochemical and molecular features.

  2022cites this paper
• The impact of uterine adenomyosis on the histopathological risk factors and survival in patients with endometrial adenocarcinoma

  2022cites this paper
• Vimentin Protein In Situ Expression Predicts Less Tumor Metastasis and Overall Better Survival of Endometrial Carcinoma

  2022cites this paper
• Clinical Value Analysis of Combined Vaginal Ultrasound, Magnetic Resonance Dispersion Weighted Imaging, and Multilayer Spiral CT in the Diagnosis of Endometrial Cancer Using Deep VGG-16 AdaBoost Hybrid Classifier

  2022cites this paper
• Current Approaches to the Management of Patients with Endometrial Cancer

  2022cites this paper
• Immunohistochemical Markers and TILs Evaluation for Endometrial Carcinoma

  2022cites this paper
• Application of NGS molecular classification in the diagnosis of endometrial carcinoma: A supplement to traditional pathological diagnosis

  2022cites this paper
• Circular RNA FOXO3 regulates endometrial carcinoma progression through the microRNA-29a-3p/HDAC4 axis.

  2022cites this paper
• Elucidation of HER2/neu and Wilms’ tumor 1 immunohistochemical expression in endometrial carcinomas regarding the diagnostic and prognostic significance

  2022cites this paper
• RETRACTED ARTICLE: Two lanthanide coordination polymers: treatment activity on the endometrial carcinoma by inhibiting the VEGF signaling pathway

  2021cites this paper
• Application of immunocytochemical and molecular analysis of six genes in liquid‐based endometrial cytology

  2021cites this paper
• Molecular Evaluation of Endometrial Dedifferentiated Carcinoma, Endometrioid Carcinoma, Carcinosarcoma, and Serous Carcinoma Using a Custom-Made Small Cancer Panel

  2021cites this paper
• Amide proton transfer imaging in differentiation of type II and type I endometrial carcinoma: a pilot study

  2021cites this paper
• Deep Learning for Intelligent Recognition and Prediction of Endometrial Cancer

  2021cites this paper
• Controversies in the Management of Early-stage Serous Endometrial Cancer

  2021cites this paper
• The role of cytology in endometrial cancer: Diagnostic and clinical considerations from peritoneal/pelvic washings. Is it still a heated debate?

  2021cites this paper
• The Clinicopathological Characteristics of Endometrial Carcinoma in Iraqi Women: Cross Sectional Study

  2020cites this paper
• Pathological features, immunoprofile and mismatch repair protein expression status in uterine endometrioid carcinoma: focus on MELF pattern of myoinvasion.

  2020cites this paper
• Pathogenesis and Clinical Management of Uterine Serous Carcinoma

  2020cites this paper
• Analysis of 108 patients with endometrial carcinoma using the PROMISE classification and additional genetic analyses for MMR-D.

  2020cites this paper
• In focus in HCB

  2020cites this paper
• In focus in HCB

  2020cites this paper
• Diagnostic and Prognostic Role of WT1 Immunohistochemical Expression in Uterine Carcinoma: A Systematic Review and Meta-Analysis across All Endometrial Carcinoma Histotypes

  2020cites this paper
• Histo-molecular features of high-grade endometrial cancers.

  2020cites this paper
• Comparison of Risk Stratification Systems for Predicting Clinical Outcomes in Patients with Endometrial Carcinoma

  2020cites this paper
• Expressions of IL-8 and CXCL5 in uterine endometrioid carcinomas which have frequent neutrophil infiltration and comparison to colorectal adenocarcinoma.

  2020cites this paper
• TWIST1 expression and clinical significance in type I endometrial cancer and premalignant lesions

  2020cites this paper
• Current recommendations and recent progress in endometrial cancer

  2019cites this paper
• Napsin A, Hepatocyte Nuclear Factor-1-Beta (HNF-1&bgr;), Estrogen and Progesterone Receptors Expression in Arias-Stella Reaction

  2019cites this paper
• Local estrogen metabolism (intracrinology) in endometrial cancer: A systematic review.

  2019cites this paper
• Provisional Guideline Recommendation for EGFR Gene Mutation Testing in Liquid Samples of Lung Cancer Patients: A Proposal by the Korean Cardiopulmonary Pathology Study Group

  2019cites this paper
• Potential Role for a Panel of Immunohistochemical Markers in the Management of Endometrial Carcinoma

  2019cites this paper
• Endometrial Carcinoma

  2018cites this paper
• Clinicopathological significance and prognostic value of myoinvasive patterns in endometrial endometrioid carcinoma.

  2018cites this paper
• PIK3CA and p53 Mutations by Next Generation Sequencing in Lymphoepithelioma-Like Carcinoma of the Endometrium

  2018cites this paper
• In focus in HCB

  2017cites this paper
• Calibration and Optimization of p53, WT1, and Napsin A Immunohistochemistry Ancillary Tests for Histotyping of Ovarian Carcinoma: Canadian Immunohistochemistry Quality Control (CIQC) Experience

  2016cites this paper
• Practical issues in the diagnosis of serous carcinoma of the endometrium

  2016cites this paper
• World Journal of Clinical Oncology

  year unknowncites this paper